The in vivo cell therapy seed Carisma Therapeutics planted with Moderna in 2022 is starting to sprout. | The in vivo cell ...

NextCure is going all in on its preclinical B7-H4-directed antibody-drug conjugate (ADC). | NextCure is going all in on its ...

Allogene Therapeutics has reported phase 1 data on its solid tumor CAR-T, linking the off-the-shelf cell therapy candidate to ...

Johnson & Johnson MedTech will enter the U.S. pulsed field ablation market following an FDA green light for its Varipulse ...

In August, Trevena underwent a reverse stock split, a move often enacted when a company’s share price dips too low. The split wasn’t enough to stave off delisting, with Nasdaq removing Trevena’s stock ...